Citi analyst Patrick Donnelly upgraded Exact Sciences to Buy from Neutral with a price target of $90, up from $70. The analyst believes the stock’s current multiple has upside as Exact returns to a "consistent beat-and-raise story," driven by Cologuard. Exact Sciences deserves to trade above the peer group and the stock’s multiple should re-rate higher on its more consistent beat-and-raise story, Cologuard’s trajectory, and the company’s profitability outlook, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on EXAS:
- Exact Sciences price target raised to $70 from $50 at Piper Sandler
- Exact Sciences price target raised to $55 from $44 at Craig-Hallum
- Exact Sciences price target raised to $76 from $56 at Cowen
- Exact Sciences price target raised to $92 from $89 at Baird
- Exact Sciences price target lowered to $80 from $85 at BTIG
